Physician profile
Joseph A Dimeo
NPI 1205848942
$8,776.70
in general payments reported to CMS, 2019-2025
44 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,705 · 2020: $1,287 · 2021: $1,137 · 2022: $952 · 2023: $1,307 · 2024: $1,429 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579 · Education: $99.99 · Debt Forgiveness: $17.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,578.77 |
| Education | $99.99 |
| Debt Forgiveness | $17.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,088.45 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Pfizer INC. | $1,028.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $695.55 | 2019-2025 | Nucala, Pediarix, Shingrix |
| Abbvie INC. | $684.78 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.72 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $596.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $325.03 | 2019-2022 | |
| Novo Nordisk INC | $295.92 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $274.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $222.84 | 2019-2024 | |
| Lilly USA, LLC | $174.37 | 2019-2023 | Mounjaro, Emgality |
| Astellas Pharma US INC | $152.54 | 2024 | Veozah |
| Amgen INC. | $134.31 | 2019-2023 | Prolia, Evenity |
| Amarin Pharma, INC. | $114.15 | 2019-2020 | |
| Exact Sciences Corporation | $108.13 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dimeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.